These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 14514474

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

  • 3. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
    Gora-Tybor J, Blonski JZ, Robak T.
    Mediators Inflamm; 2003 Jun; 12(3):167-71. PubMed ID: 12857600
    [Abstract] [Full Text] [Related]

  • 4. [Correlation of pretreatment serum level of endostatin to posttreatment distant metastasis in patients with advanced nasopharyngeal carcinoma].
    Zhao ZJ, Mo HY, Zhang CQ, Qi B, Li J, Hong MH, Mai HQ.
    Ai Zheng; 2007 Nov; 26(11):1243-7. PubMed ID: 17991326
    [Abstract] [Full Text] [Related]

  • 5. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A.
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [Abstract] [Full Text] [Related]

  • 6. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 7. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
    Kurschat P, Eming S, Nashan D, Krieg T, Mauch C.
    Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
    [Abstract] [Full Text] [Related]

  • 8. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
    Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR, Libutti SK.
    Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
    [Abstract] [Full Text] [Related]

  • 9. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
    Bono P, Teerenhovi L, Joensuu H.
    Cancer; 2003 Jun 01; 97(11):2767-75. PubMed ID: 12767089
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
    Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, Pummer K, Zigeuner R.
    Eur Urol; 2007 Jan 01; 51(1):168-73; discussion 174. PubMed ID: 16844285
    [Abstract] [Full Text] [Related]

  • 11. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS.
    Am J Hematol; 2003 Apr 01; 72(4):229-33. PubMed ID: 12666132
    [Abstract] [Full Text] [Related]

  • 12. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H, Wiersbowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2000 Sep 01; 11(3):443-51. PubMed ID: 11022130
    [Abstract] [Full Text] [Related]

  • 13. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
    Seko Y, Fukuda S, Nagai R.
    Clin Sci (Lond); 2004 May 01; 106(5):439-42. PubMed ID: 14965340
    [Abstract] [Full Text] [Related]

  • 14. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.
    Cancer; 2007 Aug 15; 110(4):824-9. PubMed ID: 17594696
    [Abstract] [Full Text] [Related]

  • 15. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG.
    Cytokine; 2011 Dec 15; 56(3):616-20. PubMed ID: 21940178
    [Abstract] [Full Text] [Related]

  • 16. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA.
    Eur J Haematol; 2004 Apr 15; 72(4):252-8. PubMed ID: 15089762
    [Abstract] [Full Text] [Related]

  • 17. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V, Kubalová D, Bacovský J, Lukes J, Vavrdová V.
    Cas Lek Cesk; 1996 Nov 20; 135(22):719-22. PubMed ID: 8998823
    [Abstract] [Full Text] [Related]

  • 18. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH, Zhao JH, Gong JP, Qin JW, Pan LQ, Xu ZY.
    Zhonghua Zhong Liu Za Zhi; 2007 Mar 20; 29(3):210-4. PubMed ID: 17649639
    [Abstract] [Full Text] [Related]

  • 19. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG, Passam FH, Kyriakou DS, Christophoridou AV, Perisinakis K, Hatzivasili A, Foudoulakis A, Castanas E.
    Am J Hematol; 2004 Feb 20; 75(2):101-6. PubMed ID: 14755377
    [Abstract] [Full Text] [Related]

  • 20. Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients.
    Tien YW, Chang KJ, Chiu YF, Huang KW, Lee PH.
    Ann Surg Oncol; 2006 Nov 20; 13(11):1357-63. PubMed ID: 17001510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.